Edwards Lifesciences Corporation $EW Shares Sold by Engineers Gate Manager LP

Engineers Gate Manager LP trimmed its position in Edwards Lifesciences Corporation (NYSE:EW) by 30.5% in the fourth quarter, Holdings Channel reports. The firm owned 232,547 shares of the medical research company’s stock after selling 102,151 shares during the quarter. Engineers Gate Manager LP’s holdings in Edwards Lifesciences were worth $19,825,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Washington Trust Advisors Inc. boosted its stake in Edwards Lifesciences by 15.6% in the third quarter. Washington Trust Advisors Inc. now owns 130,587 shares of the medical research company’s stock valued at $10,156,000 after acquiring an additional 17,625 shares during the period. Elo Mutual Pension Insurance Co boosted its stake in Edwards Lifesciences by 39.9% in the third quarter. Elo Mutual Pension Insurance Co now owns 89,674 shares of the medical research company’s stock valued at $6,974,000 after acquiring an additional 25,562 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in Edwards Lifesciences by 27.3% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 109,749 shares of the medical research company’s stock valued at $9,356,000 after acquiring an additional 23,514 shares during the period. Assenagon Asset Management S.A. boosted its stake in Edwards Lifesciences by 39.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 2,286,298 shares of the medical research company’s stock valued at $194,907,000 after acquiring an additional 648,870 shares during the period. Finally, Central Pacific Bank Trust Division acquired a new position in Edwards Lifesciences in the fourth quarter valued at approximately $775,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the sale, the chief financial officer owned 39,699 shares of the company’s stock, valued at $3,177,507.96. The trade was a 24.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president directly owned 15,334 shares in the company, valued at approximately $1,319,950.72. The trade was a 3.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 81,038 shares of company stock worth $6,683,255 in the last three months. 0.31% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

EW has been the subject of a number of research reports. Evercore restated an “outperform” rating and issued a $93.00 target price on shares of Edwards Lifesciences in a research note on Friday, April 24th. Truist Financial set a $90.00 price target on Edwards Lifesciences and gave the company a “hold” rating in a report on Friday, April 24th. BTIG Research lifted their price target on Edwards Lifesciences from $98.00 to $100.00 and gave the company a “buy” rating in a report on Friday, April 24th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a report on Monday, April 20th. Finally, TD Cowen reaffirmed a “buy” rating and set a $104.00 price target (up from $97.00) on shares of Edwards Lifesciences in a report on Tuesday, June 2nd. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $95.96.

Edwards Lifesciences Stock Performance

EW opened at $86.53 on Thursday. The business’s 50 day moving average is $83.14 and its 200-day moving average is $83.11. The stock has a market cap of $49.83 billion, a PE ratio of 46.03, a price-to-earnings-growth ratio of 2.22 and a beta of 0.87. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $89.60.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. The company had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The business’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.